Key result
Parenteral MPC sedation is linked to a ~4% rate of respiratory depression in pediatric patients.
Why the study?
Does parenteral administration of meperidine, promethazine, and chlorpromazine cause adverse respiratory effects in pediatric patients undergoing procedures?
Population
95 pediatric patients undergoing various procedures
Design
Cohort
Authors
Loading...
MPC sedation was associated with respiratory depression even at recommended doses; leaves open need for comparative safety trials versus modern alternatives.
Cohort (n=95)
Does parenteral administration of meperidine, promethazine, and chlorpromazine cause adverse respiratory effects in pediatric patients undergoing procedures?
The use of meperidine, promethazine, and chlorpromazine for pediatric sedation carries a risk of severe respiratory depression even at recommended doses, highlighting the need for strict monitoring.
Ootz et al. (1985) conducted a cohort in Pediatric patients requiring sedation for various procedures (n=95). Meperidine, promethazine, and chlorpromazine (MPC) was evaluated on Respiratory depression. Parenteral administration of meperidine, promethazine, and chlorpromazine (MPC) for sedation in 95 pediatric patients resulted in respiratory depression in 4 patients (4.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: